

Citi Pharma Limited

July 14, 2021

The General Manager,
Pakistan Stock Exchange Limited,
Stock Exchange Building,
Stock Exchange Road,
Karachi.

Subject: Material Information

Dear Sir,

In accordance with Section 96 of Securities Act, 2015 and clause 5.6.1(a) of Code of Corporate Governance contained in the PSX Rule Book, rule we hereby convey the following information:

Management of the Company is pleased to inform you the following:

Contract Manufacturing Agreement

M/s Citi Pharma Limited and CCL Pharma (Private) Limited have executed an agreement to manufacture Formulation Products on their behalf. This will lead to enhanced capacity utilization in the Company's Formulation segment.

Furthermore, this will lead to addition in the Company's profitability and net margins over the next 2 to 3 years.

You are requested to inform the members of the Exchange accordingly.

Thanks and regards.

Yours truly, for Citi Pharma Limited

Muhammad Riaz Company Secretary

Cc: The Director/HOD, Surveillance, Supervision and Enforcement, SMD, SECP, Islamabad The Executive Director, Corporate Supervision Department, SECP, Islamabad